Month: February 2025

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025 Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025 Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgANBRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the fourth quarter and full year ended...

Record 2024 revenue with growth of 3% with organic growth of 12% Continued robust organic growth of 23% in AMS/DRS and 9% in CVMStrong 2024 cash generation with cash from operations of $426M and free cash flow of $400M Reduced net leverage while returning $245M in cash to shareholders RICHMOND, Va., Feb. 26, 2025 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced fourth-quarter and full-year 2024 results. Mark Eubanks, president and CEO, said: “2024 completes another year of strategic progress as we continue to transform Brink’s into a faster growing, more profitable and higher cash flow generating business. Over the year, we accelerated organic growth in AMS and DRS, expanded our EBITDA...

TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the year ended December 31, 2024. Management commentary “Sprott’s Assets Under Management (“AUM”) ended the year at $31.5 billion, down 6% from $33.4 billion as at September 30, 2024, but up 10% from $28.7 billion as at December 31, 2023. 2024 was our seventh consecutive year of double-digit AUM growth and, subsequent to year-end, as at February 21, 2025, AUM had further increased to $33.5 billion, up $2 billion, or 6% from December 31, 2024,” said Whitney George, Chief Executive Officer of Sprott. “During the year we benefited from strong precious metals prices as well as $698 million in net sales, primarily in our physical trusts and uranium and critical materials ETFs.” “The...

BANNOCKBURN, Ill., Feb. 26, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsNet revenue of $1,346.4 million, up 19.7% compared to $1,124.4 million in the fourth quarter of 2023 Gross profit of $268.4 million, or 19.9% of net revenue, up 8.6% compared to $247.1 million, or 22.0% of net revenue, in the fourth quarter of 2023 Net income of $60.1 million, compared to net income of $57.2 million, in the fourth quarter of 2023 and diluted earnings per share of $0.35, up 9.4% compared to diluted earnings per share of $0.32 in the fourth quarter of 2023 Adjusted...

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectively As of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents, restricted cash and marketable securities of $931.3 million at December 31, 2024 Announces new two-year data for the active-treatment open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial Company to host conference call today, February 26, 2025, at 8 a.m. ESTCONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports fourth-quarter and year-end 2024 financial results and reviews business highlights. Bill Sibold, Chief Executive...

Fourth Quarter Highlights(All metrics compared to the fourth quarter of fiscal 2024)Contract revenues of $1.085 billion, up 13.9% Adjusted EBITDA of $116.4 million, or 10.7% of contract revenues, up 89 basis points Net income of $32.7 million, or $1.11 per common share diluted Adjusted Net Income of $34.5 million; Adjusted EPS of $1.17 per common share diluted, up 48.1% Total backlog of $7.760 billion as of January 25, 2025 Repurchased 200,000 shares for $35.9 millionAnnual Highlights(All metrics compared to fiscal 2024)Contract revenues of $4.702 billion, up 12.6% Adjusted EBITDA of $576.3 million, or 12.3% of contract revenues Net income of $233.4 million, or $7.92 per common share diluted Adjusted Net Income of $248.7 million; Adjusted EPS of $8.44 per common share diluted, up 24.5% Operating Cash Flow of $349.1 million, up 34.8% Repurchased...

BROOKFIELD, Conn., Feb. 26, 2025 (GLOBE NEWSWIRE) — Photronics, Inc. (NASDAQ:PLAB), a worldwide leader in photomask technologies and solutions, today reported financial results for its first quarter of fiscal year 2025 ended February 2, 2025. “We achieved top-line results in line with our expectations and reflective of seasonal demand patterns,” said Frank Lee, chief executive officer. “Within Integrated Circuits (IC) and Flat Panel Display (FPD) end markets, we observed favorable demand for high-end products while the most mature mainstream masks were impacted by general market softness. In IC, photomasks supporting node migration and memory were particularly strong. In FPD, we continue to strategically leverage our IC technical expertise to drive our market leading position and market share gains. We remain cautious about 2025,...

— Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million — — On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 —  — Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity — — FDA approved expanded label for IMCIVREE to include children as young as 2 years old — — Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 — — Management to host conference call today at 8:00 a.m. ET — BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...